JP2024528195A - ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物 - Google Patents

ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物 Download PDF

Info

Publication number
JP2024528195A
JP2024528195A JP2024506610A JP2024506610A JP2024528195A JP 2024528195 A JP2024528195 A JP 2024528195A JP 2024506610 A JP2024506610 A JP 2024506610A JP 2024506610 A JP2024506610 A JP 2024506610A JP 2024528195 A JP2024528195 A JP 2024528195A
Authority
JP
Japan
Prior art keywords
propylene glycol
pharmaceutical composition
liquid
liquid pharmaceutical
castor oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528195A5 (https=
Inventor
ギブソン，クリストフ
Original Assignee
ファルバリス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルバリス ゲーエムベーハー filed Critical ファルバリス ゲーエムベーハー
Publication of JP2024528195A publication Critical patent/JP2024528195A/ja
Publication of JP2024528195A5 publication Critical patent/JP2024528195A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024506610A 2021-08-05 2022-08-05 ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物 Pending JP2024528195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21189990 2021-08-05
EP21189990.1 2021-08-05
PCT/EP2022/072049 WO2023012322A1 (en) 2021-08-05 2022-08-05 Lipid-based composition for oral administration of bradykinin b2-receptor antagonists

Publications (2)

Publication Number Publication Date
JP2024528195A true JP2024528195A (ja) 2024-07-26
JP2024528195A5 JP2024528195A5 (https=) 2025-08-01

Family

ID=77226756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506610A Pending JP2024528195A (ja) 2021-08-05 2022-08-05 ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物

Country Status (25)

Country Link
US (1) US20240350418A1 (https=)
EP (1) EP4203919B1 (https=)
JP (1) JP2024528195A (https=)
KR (1) KR20240039185A (https=)
CN (1) CN118076342B (https=)
AU (1) AU2022323749A1 (https=)
BR (1) BR112024002215A2 (https=)
CA (1) CA3227476A1 (https=)
CO (1) CO2024001171A2 (https=)
DK (1) DK4203919T3 (https=)
ES (1) ES2978563T3 (https=)
FI (1) FI4203919T3 (https=)
HR (1) HRP20240525T1 (https=)
HU (1) HUE066306T2 (https=)
IL (1) IL310321A (https=)
LT (1) LT4203919T (https=)
MA (1) MA61123B1 (https=)
MX (1) MX2024001711A (https=)
PL (1) PL4203919T3 (https=)
PT (1) PT4203919T (https=)
RS (1) RS65427B1 (https=)
SI (1) SI4203919T1 (https=)
SM (1) SMT202400157T1 (https=)
WO (1) WO2023012322A1 (https=)
ZA (1) ZA202401504B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224522B (zh) * 2023-11-15 2024-02-23 北京协和药厂有限公司 药物组合物及其制备方法、药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2218554T3 (es) 1994-10-27 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina.
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
JP2002517461A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド ブラジキニンアンタゴニスト
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
WO2008055146A2 (en) * 2006-10-31 2008-05-08 Wyeth Formulations of phospholipase enzyme inhibitors
TWI407960B (zh) 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽ｂ２受體調節劑
AR073304A1 (es) 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
WO2014159637A1 (en) 2013-03-14 2014-10-02 Shire Human Genetic Therapies, Inc. Methods of treating b2-bradykinin receptor mediated angioedema
AR113839A1 (es) 2017-11-24 2020-06-17 Pharvaris B V Antagonistas del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
ES2978563T3 (es) 2024-09-16
PL4203919T3 (pl) 2024-06-10
FI4203919T3 (fi) 2024-05-03
KR20240039185A (ko) 2024-03-26
SI4203919T1 (sl) 2024-08-30
RS65427B1 (sr) 2024-05-31
US20240350418A1 (en) 2024-10-24
PT4203919T (pt) 2024-04-23
EP4203919A1 (en) 2023-07-05
EP4203919B1 (en) 2024-01-31
CN118076342B (zh) 2025-08-05
HUE066306T2 (hu) 2024-07-28
ZA202401504B (en) 2025-06-25
MA61123B1 (fr) 2024-06-28
CA3227476A1 (en) 2023-02-09
CO2024001171A2 (es) 2024-05-20
CN118076342A (zh) 2024-05-24
AU2022323749A1 (en) 2024-02-08
DK4203919T3 (da) 2024-04-29
BR112024002215A2 (pt) 2024-04-30
SMT202400157T1 (it) 2024-05-14
IL310321A (en) 2024-03-01
WO2023012322A1 (en) 2023-02-09
MX2024001711A (es) 2024-03-05
TW202320774A (zh) 2023-06-01
LT4203919T (lt) 2024-05-10
HRP20240525T1 (hr) 2024-07-05

Similar Documents

Publication Publication Date Title
TWI764996B (zh) 含西里帕格之醫藥組成物
JP5671451B2 (ja) ＧｎＲＨ関連化合物の組成物および調製プロセス
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
TW201114766A (en) Pharmaceutical composition for a hepatitis C viral protease inhibitor
AU2014261009A1 (en) Compositions of pharmaceutical actives containing Diethylene glycol monoethyl ether or other alkyl derivatives
CN115052584B (zh) 治疗性化合物及其制剂和用途
CA2800279A1 (en) Oral dosage forms of bendamustine
JP2024528195A (ja) ブラジキニンｂ２受容体拮抗薬を経口投与するための脂質ベースの組成物
WO2008087076A1 (en) Pharmaceutical composition of improved stability containing taxane derivatives
KR20000069308A (ko) Ｎ-설포닐인돌린 유도체를 포함하는 약학적 조성물
JP6014252B2 (ja) ネパデュタントを含有する小児用経口液体組成物
ES3062067T3 (en) Solid composition comprising solubilised bradykinin b2-receptor antagonists
JP5503939B2 (ja) アゼラスチン塩酸塩含有カプセル剤
EA051972B1 (ru) Композиция на основе липидов для перорального применения антагонистов брадикининовых b2-рецепторов
HK40088043B (en) Lipid-based composition for oral administration of bradykinin b2-receptor antagonists
HK40088043A (en) Lipid-based composition for oral administration of bradykinin b2-receptor antagonists
ES2824818T3 (es) Cápsulas de gelatina blanda que comprenden una suspensión de tadalafilo
TW202135806A (zh) 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物
EA046628B1 (ru) Терапевтические соединения, их составы и применения
KR20160090312A (ko) 조산 조건의 치료에서 사용을 위한 용량 단위의 조합

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250723